Kjell Magne Tveit

  • Professor; MD, PhD
  • +47 23 02 78 30

Publications 2022

Smedman TM, Guren TK, Tveit KM, Thomsen M, Andersen MH, Line PD, Dueland S (2022)
Health-Related Quality of Life in Colorectal Cancer Patients Treated With Liver Transplantation Compared to Chemotherapy
Transpl Int, 35, 10404
DOI 10.3389/ti.2022.10404, PubMed 35707633

Publications 2021

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Int J Cancer, 149 (6), 1385-1397
DOI 10.1002/ijc.33672, PubMed 33961700

Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG (2021)
Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022

Olsen F, Jacobsen BK, Heuch I, Tveit KM, Balteskard L (2021)
Equitable access to cancer patient pathways in Norway - a national registry-based study
BMC Health Serv Res, 21 (1), 1272
DOI 10.1186/s12913-021-07250-1, PubMed 34823515

Publications 2019

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Ann Oncol, 30 (7), 1088-1095
DOI 10.1093/annonc/mdz139, PubMed 31046124

Publications 2018

Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, Eide TJ, Skovlund E, Lekven J, Schneede J, Tveit KM, Vatn M, Ursin G, Hoff G, NORCCAP Study Group† (2018)
Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial
Ann Intern Med, 168 (11), 775-782
DOI 10.7326/M17-1441, PubMed 29710125

Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
DOI 10.1038/s41416-018-0115-9, PubMed 29872151

Publications 2017

Bryhn B, Tveit KM (2017)
[Not Available]
Tidsskr Nor Laegeforen, 137 (21)
DOI 10.4045/tidsskr.17.0889, PubMed 29135165

Bryhn B, Tveit KM (2017)
National intestinal screening will reduce the occurrence and mortality of intestinal cancer
Tidsskr. Nor. Laegeforen., 137 (21), 1664

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM (2017)
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Br J Cancer, 116 (10), 1271-1278
DOI 10.1038/bjc.2017.93, PubMed 28399112

Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Eur J Cancer, 81, 26-35
DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137

Publications 2016

Mezheyeuski A, Bradic Lindh M, Guren TK, Dragomir A, Pfeiffer P, Kure EH, Ikdahl T, Skovlund E, Corvigno S, Strell C, Pietras K, Ponten F, Mulder J, Qvortrup C, Portyanko A, Tveit KM, Glimelius B, Sorbye H, Östman A (2016)
Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
Oncotarget, 7 (27), 41948-41958
DOI 10.18632/oncotarget.9632, PubMed 27248825

Tarpgaard LS, Ørum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, Glimelius B, Sorbye H, Ikdahl T, Kure EH, Tveit KM, Nielsen HJ, Pfeiffer P, Brünner N, Moreira JM (2016)
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer
Oncotarget, 7 (37), 59441-59457
DOI 10.18632/oncotarget.11118, PubMed 27509063

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Oncotarget, 7 (46), 75013-75022
DOI 10.18632/oncotarget.12601, PubMed 27738330

Publications 2015

Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, Foss A, Tveit KM (2015)
Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?
Ann Surg, 261 (5), 956-60
DOI 10.1097/SLA.0000000000000786, PubMed 24950280

Kjersem JB, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit KM, Wettergren Y, Kure EH (2015)
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
Pharmacogenomics J, 16 (3), 272-9
DOI 10.1038/tpj.2015.54, PubMed 26261061

Tarpgaard LS, Christensen IJ, Høyer-Hansen G, Lund IK, Guren TK, Glimelius B, Sorbye H, Tveit KM, Nielsen HJ, Moreira JM, Pfeiffer P, Brünner N (2015)
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab
Int J Cancer, 137 (10), 2470-7
DOI 10.1002/ijc.29476, PubMed 25664394

Publications 2014

Asli LM, Kvaløy SO, Jetne V, Myklebust TÅ, Levernes SG, Tveit KM, Green TO, Johannesen TB (2014)
Utilization of radiation therapy in Norway after the implementation of the national cancer plan--a national, population-based study
Int J Radiat Oncol Biol Phys, 90 (3), 707-14
DOI 10.1016/j.ijrobp.2014.06.059, PubMed 25160610

Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A (2014)
Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?
Ann Surg Oncol, 22 (7), 2195-200
DOI 10.1245/s10434-014-4137-0, PubMed 25297902

Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, Glynne-Jones R, Tveit KM (2014)
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395

Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM, Gibson F (2014)
A review of the evolution of systemic chemotherapy in the management of colorectal cancer
Clin Colorectal Cancer, 14 (1), 1-10
DOI 10.1016/j.clcc.2014.11.002, PubMed 25579803

Hauglann B, Benth JS, Fosså SD, Tveit KM, Dahl AA (2014)
A controlled cohort study of long-term income in colorectal cancer patients
Support Care Cancer, 22 (10), 2821-30
DOI 10.1007/s00520-014-2258-4, PubMed 24821364

Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, Eide TJ, Skovlund E, Schneede J, Tveit KM, Hoff G (2014)
Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial
JAMA, 312 (6), 606-15
DOI 10.1001/jama.2014.8266, PubMed 25117129

Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH (2014)
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
BMC Cancer, 14, 340
DOI 10.1186/1471-2407-14-340, PubMed 24884501

Leon O, Guren M, Hagberg O, Glimelius B, Dahl O, Havsteen H, Naucler G, Svensson C, Tveit KM, Jakobsen A, Pfeiffer P, Wanderås E, Ekman T, Lindh B, Balteskard L, Frykholm G, Johnsson A (2014)
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines
Radiother Oncol, 113 (3), 352-8
DOI 10.1016/j.radonc.2014.10.002, PubMed 25499203

Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM (2014)
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
PLoS One, 9 (2), e87746
DOI 10.1371/journal.pone.0087746, PubMed 24498368

Wiig JN, Giercksky KE, Tveit KM (2014)
Intraoperative radiotherapy for locally advanced or locally recurrent rectal cancer: Does it work at all?
Acta Oncol, 53 (7), 865-76
DOI 10.3109/0284186X.2014.895037, PubMed 24678823

Publications 2013

Hauglann BK, Saltytė Benth J, Fosså SD, Tveit KM, Dahl AA (2013)
A controlled cohort study of sickness absence and disability pension in colorectal cancer survivors
Acta Oncol, 53 (6), 735-43
DOI 10.3109/0284186X.2013.844354, PubMed 24345277

Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH (2013)
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
Mol Oncol, 8 (1), 59-67
DOI 10.1016/j.molonc.2013.09.001, PubMed 24119443

Sveen A, Nesbakken A, Ågesen TH, Guren MG, Tveit KM, Skotheim RI, Lothe RA (2013)
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Clin Cancer Res, 19 (24), 6669-77
DOI 10.1158/1078-0432.CCR-13-1769, PubMed 24166914

Publications 2012

Bentzen AG, Guren MG, Wanderås EH, Frykholm G, Tveit KM, Wilsgaard T, Dahl O, Balteskard L (2012)
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort
Int J Radiat Oncol Biol Phys, 83 (2), e173-80
DOI 10.1016/j.ijrobp.2011.12.062, PubMed 22436791

Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2012)
Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing
PLoS One, 7 (4), e34150
DOI 10.1371/journal.pone.0034150, PubMed 22529906

Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH (2012)
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
BMC Cancer, 12, 534
DOI 10.1186/1471-2407-12-534, PubMed 23167843

Kure EH, Hamfjord J, Stangeland AM, Tveit KM, Ikdahl T (2012)
KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem
Expert Rev Mol Diagn, 12 (4), 327-8
DOI 10.1586/erm.12.29, PubMed 22616697

Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, Fluge Ø, Vonen B, Myrvold HE, Leh S, Tveit KM, Pestell RG, Dahl O (2012)
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
Br J Cancer, 107 (10), 1684-91
DOI 10.1038/bjc.2012.463, PubMed 23099809

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012)
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
J Clin Oncol, 30 (15), 1755-62
DOI 10.1200/JCO.2011.38.0915, PubMed 22473155

Publications 2011

Bornholdt J, Friis S, Godiksen S, Poulsen SS, Santoni-Rugiu E, Bisgaard HC, Lothe IM, Ikdahl T, Tveit KM, Johnson E, Kure EH, Vogel LK (2011)
The level of claudin-7 is reduced as an early event in colorectal carcinogenesis
BMC Cancer, 11, 65
DOI 10.1186/1471-2407-11-65, PubMed 21310043

Brændengen M, Tveit KM, Hjermstad MJ, Johansson H, Berglund Å, Brandberg Y, Glimelius B (2011)
Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study
Eur J Cancer, 48 (6), 813-9
DOI 10.1016/j.ejca.2011.06.035, PubMed 21782418

Hamfjord J, Stangeland AM, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2011)
Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations
Diagn Mol Pathol, 20 (3), 158-65
DOI 10.1097/PDM.0b013e31820b49e2, PubMed 21817902

Publications 2010

Bruheim K, Tveit KM, Skovlund E, Balteskard L, Carlsen E, Fosså SD, Guren MG (2010)
Sexual function in females after radiotherapy for rectal cancer
Acta Oncol, 49 (6), 826-32
DOI 10.3109/0284186X.2010.486411, PubMed 20615170

Brændengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund Å, Glimelius B (2010)
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study
Int J Radiat Oncol Biol Phys, 81 (4), 1017-24
DOI 10.1016/j.ijrobp.2010.07.007, PubMed 20932687

Publications 2009

Bruheim K, Guren MG, Dahl AA, Skovlund E, Balteskard L, Carlsen E, Fosså SD, Tveit KM (2009)
Sexual function in males after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1012-7
DOI 10.1016/j.ijrobp.2009.03.075, PubMed 19880263

Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, Carlsen E, Tveit KM (2009)
Late side effects and quality of life after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1005-11
DOI 10.1016/j.ijrobp.2009.03.010, PubMed 19540058

Baatrup G, Endreseth BH, Isaksen V, Kjellmo A, Tveit KM, Nesbakken A (2009)
Preoperative staging and treatment options in T1 rectal adenocarcinoma
Acta Oncol, 48 (3), 328-42
DOI 10.1080/02841860802657243, PubMed 19180365

Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group (2009)
Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group
Acta Oncol, 48 (3), 368-76
DOI 10.1080/02841860902755244, PubMed 19242829

Fluge Ø, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, Lilleng R, Eide TJ, Halvorsen TB, Tveit KM, Otte AP, Akslen LA, Dahl O, Norwegian Gastrointestinal Cancer Group (2009)
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
Br J Cancer, 101 (8), 1282-9
DOI 10.1038/sj.bjc.6605333, PubMed 19773751

Jetne V, Kvaløy S, Smeland S, Johannesen TB, Tveit KM (2009)
[Use of radiotherapy in South-Eastern Norway Regional Health Authority]
Tidsskr Nor Laegeforen, 129 (24), 2602-5
DOI 10.4045/tidsskr.09.0331, PubMed 20029555

Selzer-Plon J, Bornholdt J, Friis S, Bisgaard HC, Lothe IM, Tveit KM, Kure EH, Vogel U, Vogel LK (2009)
Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis
BMC Cancer, 9, 201
DOI 10.1186/1471-2407-9-201, PubMed 19555470

Skovbjerg H, Anthonsen D, Lothe IM, Tveit KM, Kure EH, Vogel LK (2009)
Collagen mRNA levels changes during colorectal cancer carcinogenesis
BMC Cancer, 9, 136
DOI 10.1186/1471-2407-9-136, PubMed 19422682

Publications 2008

Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K, Glimelius B (2008)
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer
J Clin Oncol, 26 (22), 3687-94
DOI 10.1200/JCO.2007.15.3858, PubMed 18669453

Bruheim K, Svartberg J, Carlsen E, Dueland S, Haug E, Skovlund E, Tveit KM, Guren MG (2008)
Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH
Int J Radiat Oncol Biol Phys, 70 (3), 722-7
DOI 10.1016/j.ijrobp.2007.10.043, PubMed 18262088

Glimelius B, Sørbye H, Balteskard L, Byström P, Pfeiffer P, Tveit K, Heikkilä R, Keldsen N, Albertsson M, Starkhammar H, Garmo H, Berglund A (2008)
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
Ann Oncol, 19 (5), 909-14
DOI 10.1093/annonc/mdm588, PubMed 18209013

Qvortrup C, Yilmaz M, Ogreid D, Berglund A, Balteskard L, Ploen J, Fokstuen T, Starkhammar H, Sørbye H, Tveit K, Pfeiffer P (2008)
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil
Ann Oncol, 19 (6), 1154-9
DOI 10.1093/annonc/mdn002, PubMed 18281265

Saebø M, Skjelbred CF, Brekke Li K, Bowitz Lothe IM, Hagen PC, Johnsen E, Tveit KM, Kure EH (2008)
CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas
Anticancer Res, 28 (4C), 2289-95
PubMed 18751408

Publications 2007

Balteskard L, Vonen B, Frykholm G, Dahl O, Tveit KM (2007)
[Radiotherapy of rectal cancer]
Tidsskr Nor Laegeforen, 127 (23), 3090-3
PubMed 18049501

Gaard M, Vonen B, Tveit KM, Hoff G, Carlsen E (2007)
[Colorectal cancer registry]
Tidsskr Nor Laegeforen, 127 (21), 2834-5
PubMed 17987076

Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C (2007)
Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma
BMC Cancer, 7, 192
DOI 10.1186/1471-2407-7-192, PubMed 17935612

Skjelbred CF, Saebø M, Hjartåker A, Grotmol T, Hansteen IL, Tveit KM, Hoff G, Kure EH (2007)
Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas
BMC Cancer, 7, 228
DOI 10.1186/1471-2407-7-228, PubMed 18093316

Sørbye H, Berglund A, Tveit KM, Ogreid D, Wanderås EH, Wentzel-Larsen T, Dahl O, Glimelius B (2007)
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer
Acta Oncol, 46 (7), 982-8
DOI 10.1080/02841860701261568, PubMed 17917829

Tveit KM (2007)
[Multimodal treatment in colorectal cancer]
Tidsskr Nor Laegeforen, 127 (23), 3055
PubMed 18049492

Publications 2006

Wibe A, Carlsen E, Dahl O, Tveit KM, Weedon-Fekjaer H, Hestvik UE, Wiig JN, Norwegian Rectal Cancer Group (2006)
Nationwide quality assurance of rectal cancer treatment
Colorectal Dis, 8 (3), 224-9
DOI 10.1111/j.1463-1318.2005.00924.x, PubMed 16466564

Aass N, Bjordal K, Tveit KM, Nordøy T (2006)
[Tumour-modifying therapy]
Tidsskr Nor Laegeforen, 126 (5), 628-32
PubMed 16505877

Publications 2005

Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, Grönberg H, Hultborn R, Albertsson M, Påhlman L, Tveit KM, Nordic Gastrointestinal Tumour Adjuvant Therapy Group (2005)
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group
Acta Oncol, 44 (8), 904-12
DOI 10.1080/02841860500355900, PubMed 16332600

Guren MG, Eriksen MT, Wiig JN, Carlsen E, Nesbakken A, Sigurdsson HK, Wibe A, Tveit KM, Norwegian Rectal Cancer Group (2005)
Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer
Eur J Surg Oncol, 31 (7), 735-42
DOI 10.1016/j.ejso.2005.05.004, PubMed 16180267

Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM (2005)
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen, 125 (22), 3115-9
PubMed 16299568

Pfeiffer P, Sørbye H, Ehrsson H, Fokstuen T, Mortensen JP, Baltesgard L, Tveit KM, Øgreid D, Starkhammar H, Wallin I, Qvortrup C, Glimelius B (2005)
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil
Ann Oncol, 17 (2), 252-8
DOI 10.1093/annonc/mdj060, PubMed 16291583

Tveit KM, Kataja VV, ESMO Guidelines Task Force (2005)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer
Ann Oncol, 16 Suppl 1, i20-1
DOI 10.1093/annonc/mdi827, PubMed 15888739

Publications 2004

Axon AT, Beilenhoff U, James T, Ladas SD, Larsen E, Neumann CS, Nowak A, Schöfl R, Tveit KM (2004)
Legal and Ethical Considerations: Group 4 Report. ESGE/UEGF Colorectal Cancer--Public Awareness Campaign. The Public/Professional Interface Workshop: Oslo, Norway, June 20 - 22, 2003
Endoscopy, 36 (4), 362-5
DOI 10.1055/s-2004-814289, PubMed 15057692

Guren MG, Schneede J, Tveit KM, Ueland PM, Nexø E, Dueland S (2004)
Biochemical signs of impaired cobalamin status during and after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 60 (3), 807-13
DOI 10.1016/j.ijrobp.2004.04.018, PubMed 15465197

Schoemaker NE, Kuppens IE, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, Richel DJ, Smaaland R, Bertelsen K, Poulsen JP, Voznyi E, Norum J, Fennelly D, Tveit KM, Garin A, Gruia G, Mourier A, Sibaud D, Lefebvre P, Beijnen JH, Schellens JH, ten Bokkel Huinink WW (2004)
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
Br J Cancer, 91 (8), 1434-41
DOI 10.1038/sj.bjc.6602172, PubMed 15381932

Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Øgreid D, Dahl O (2004)
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer
J Clin Oncol, 22 (1), 31-8
DOI 10.1200/JCO.2004.05.188, PubMed 14701765

Publications 2003

Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM (2003)
Epidermal growth factor receptor inhibition induces trichomegaly
Acta Oncol, 42 (4), 345-6
DOI 10.1080/02841860310006038, PubMed 12899508

Guren MG, Dueland S, Skovlund E, Fosså SD, Poulsen JP, Tveit KM (2003)
Quality of life during radiotherapy for rectal cancer
Eur J Cancer, 39 (5), 587-94
DOI 10.1016/s0959-8049(02)00741-4, PubMed 12628837

Tveit KM, ESMO Guidelines Task Force (2003)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer
Ann Oncol, 14 (7), 1006-7
DOI 10.1093/annonc/mdg297, PubMed 12853337

Publications 2002

Bretthauer M, Gondal G, Larsen K, Carlsen E, Eide TJ, Grotmol T, Skovlund E, Tveit KM, Vatn MH, Hoff G (2002)
Design, organization and management of a controlled population screening study for detection of colorectal neoplasia: attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention)
Scand J Gastroenterol, 37 (5), 568-73
DOI 10.1080/00365520252903125, PubMed 12059059

Glimelius B, Ristamäki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, Linné T, Frödin JE, Boussard B, Oulid-Aïssa D, Pyrhönen S (2002)
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
Ann Oncol, 13 (12), 1868-73
DOI 10.1093/annonc/mdf324, PubMed 12453854

Kringen P, Egedal S, Pedersen JC, Harbitz TB, Tveit KM, Berg K, Børresen-Dale AL, Andersen TI (2002)
BRCA1 mutation screening using restriction endonuclease fingerprinting-single-strand conformation polymorphism in an automated capillary electrophoresis system
Electrophoresis, 23 (24), 4085-91
DOI 10.1002/elps.200290025, PubMed 12481264

Tveit KM (2002)
Liver metastases from colorectal cancer--more cures awaiting?
Acta Oncol, 41 (7-8), 578-81
PubMed 14651200

Tveit KM, Wist E, Wiig JN (2002)
Tarmkreft: informasjon om tarmkreft for pasienter pårørende og andreinteresserte
In Kreftinfo, Den norske kreftforening, Oslo, 6/2002 (4. oppl.), 25 s.
BIBSYS 030466571

Wiig JN, Tveit KM, Poulsen JP, Olsen DR, Giercksky KE (2002)
Preoperative irradiation and surgery for recurrent rectal cancer. Will intraoperative radiotherapy (IORT) be of additional benefit? A prospective study
Radiother Oncol, 62 (2), 207-13
DOI 10.1016/s0167-8140(01)00486-8, PubMed 11937248

Publications 2001

Guren MG, Wiig JN, Dueland S, Tveit KM, Fosså SD, Waehre H, Giercksky KE (2001)
Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer
Eur J Surg Oncol, 27 (7), 645-51
DOI 10.1053/ejso.2001.1195, PubMed 11669593

Publications 2000

Wiig JN, Poulsen JP, Tveit KM, Olsen DR, Giercksky KE (2000)
Intra-operative irradiation (IORT) for primary advanced and recurrent rectal cancer. a need for randomised studies
Eur J Cancer, 36 (7), 868-74
DOI 10.1016/s0959-8049(00)00015-0, PubMed 10785591

Publications 1999

Tveit KM (1999)
Radiotherapy in rectal cancer
Acta Oncol, 38 (1), 5-6
DOI 10.1080/028418699431744, PubMed 10090683

Tveit KM (1999)
Kolorektalcancer og analcancer: en veiledning for leger
Gruppen, Oslo, 67 s.
BIBSYS 99162646x

Wiig JN, Wolff PA, Tveit KM, Giercksky KE (1999)
Location of pelvic recurrence after 'curative' low anterior resection for rectal cancer
Eur J Surg Oncol, 25 (6), 590-4
DOI 10.1053/ejso.1999.0712, PubMed 10556005

Publications 1998

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dørum A, Møller P, Weber BL, Børresen-Dale AL (1998)
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening
Hum Mutat, 11 (2), 166-74
DOI 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X, PubMed 9482581

Geisler J, Geisler SB, Lønning PE, Smaaland R, Tveit KM, Refsum H, Ueland PM (1998)
Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients
Clin Cancer Res, 4 (9), 2125-8
PubMed 9748129

Helle SI, Geisler J, Poulsen JP, Hestdal K, Meadows K, Collins W, Tveit KM, Holly JM, Lønning PE (1998)
Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study
Br J Cancer, 78 (1), 14-20
DOI 10.1038/bjc.1998.435, PubMed 9662244

Suo Z, Emilsen E, Tveit KM, Nesland JM (1998)
Type 1 protein tyrosine kinases in benign and malignant breast lesions
Histopathology, 33 (6), 514-21
DOI 10.1046/j.1365-2559.1998.00498.x, PubMed 9870145

Tveit KM, Nordlinger B, Penna C, Schmoll HJ (1998)
Is there a standard adjuvant treatment for rectal cancer?
Eur J Cancer, 34 (12), 1827-35
DOI 10.1016/s0959-8049(98)00257-3, PubMed 10023302

Publications 1997

Anderson TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Elles R, Tveit KM, Johnston SR, Dowsett M, Olsen AO, Møller P, Stratton MR, Børresen-Dale AL (1997)
Screening for ESR mutations in breast and ovarian cancer patients
Hum Mutat, 9 (6), 531-6
DOI 10.1002/(SICI)1098-1004(1997)9:6<531::AID-HUMU6>3.0.CO;2-4, PubMed 9195227

Tveit KM (1997)
[Adjuvant treatment in operable colonic and rectal cancer. A new possibility]
Tidsskr Nor Laegeforen, 117 (20), 2991-2
PubMed 9340862

Tveit KM (1997)
[Cytostatic treatment by general practitioners?]
Tidsskr Nor Laegeforen, 117 (27), 3911-2
PubMed 9441412

Tveit KM, Guldvog I, Hagen S, Trondsen E, Harbitz T, Nygaard K, Nilsen JB, Wist E, Hannisdal E (1997)
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group
Br J Surg, 84 (8), 1130-5
DOI 10.1002/bjs.1800840827, PubMed 9278661

Tveit KM, Wiig JN, Olsen DR, Storaas A, Poulsen JP, Giercksky KE (1997)
Combined modality treatment including IORT in locally advanced and recurrent rectal cancer: results from a prospective Norwegian study
Front Radiat Ther Oncol, 31, 221-3
DOI 10.1159/000061129, PubMed 9263827

Tveit KM, Wiig JN, Olsen DR, Storaas A, Poulsen JP, Giercksky KE (1997)
Combined modality treatment including intraoperative radiotherapy in locally advanced and recurrent rectal cancer
Radiother Oncol, 44 (3), 277-82
DOI 10.1016/s0167-8140(97)00070-4, PubMed 9380828

Publications 1996

Bjerkeset T, Dahl O, Gerner T, Tveit KM (1996)
[Treatment of fixed, primarily non-resected rectal cancer. Recommendations from Norwegian Gastrointestinal Cancer Group]
Tidsskr Nor Laegeforen, 116 (3), 379-81
PubMed 8638268

Tveit KM, Dahl O, Gerner T (1996)
[Chemotherapy in colorectal cancer. Recommendations of the Norwegian Gastrointestinal Cancer Group]
Tidsskr Nor Laegeforen, 116 (3), 357-60
PubMed 8638262

Wiig JN, Berner A, Tveit KM, Giercksky KE (1996)
Evaluation of digitally guided fine needle aspiration cytology versus fine needle core biopsy for the diagnosis of recurrent rectal cancer
Int J Colorectal Dis, 11 (6), 272-5
DOI 10.1007/s003840050060, PubMed 9007621

Publications 1995

Olsen DR, Paulsen TH, Heyerdal H, Tveit KM, Wiig JN, Giercksky KE, Storaas A (1995)
Field homogeneity of bevelled intraoperative electron beam cones: the influence of virtual focus surface distance
Med Dosim, 20 (2), 105-9
DOI 10.1016/0958-3947(95)00011-k, PubMed 7632342

Publications 1994

Hum. Genet., 94 (6), 665-670

Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Børresen AL (1994)
Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility
Hum Genet, 94 (6), 665-70
DOI 10.1007/BF00206961, PubMed 7989041

Hannisdal E, Tveit KM, Theodorsen L, Høst H (1994)
Host markers and prognosis in recurrent rectal carcinomas treated with radiotherapy
Acta Oncol, 33 (4), 415-21
DOI 10.3109/02841869409098438, PubMed 8018375

Kaern J, Tropé CG, Kristensen GB, Tveit KM, Pettersen EO (1994)
Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study
Am J Obstet Gynecol, 170 (2), 479-87
DOI 10.1016/s0002-9378(94)70215-2, PubMed 8116701

Publications 1993

Ottestad L, Andersen TI, Nesland JM, Skrede M, Tveit KM, Nustad K, Børresen AL (1993)
Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis
Acta Oncol, 32 (3), 289-94
DOI 10.3109/02841869309093597, PubMed 8100712

Ottestad L, Pettersen EO, Nesland JM, Hannisdal E, Fosså SD, Tveit KM (1993)
Flow cytometric DNA analysis as prognostic factor in human breast carcinoma
Pathol Res Pract, 189 (4), 405-10
DOI 10.1016/S0344-0338(11)80327-4, PubMed 8351241

Søvik E, Lien HH, Tveit KM (1993)
Postirradiation changes in the pelvic wall. Findings on MR
Acta Radiol, 34 (6), 573-6
PubMed 8240891

Tanum G, Tveit KM, Karlsen KO (1993)
Chemoradiotherapy of anal carcinoma: tumour response and acute toxicity
Oncology, 50 (1), 14-7
DOI 10.1159/000227140, PubMed 8421594

Tveit KM (1993)
[Treatment of anal cancer]
Tidsskr Nor Laegeforen, 113 (28), 3452-3
PubMed 8273073

Publications 1992

Andersen TI, Gaustad A, Ottestad L, Farrants GW, Nesland JM, Tveit KM, Børresen AL (1992)
Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas
Genes Chromosomes Cancer, 4 (2), 113-21
DOI 10.1002/gcc.2870040203, PubMed 1373310

Lien HH, Blomlie V, Talle K, Tveit KM (1992)
Radiation-induced fracture of the sacrum: findings on MR
AJR Am J Roentgenol, 159 (1), 227
DOI 10.2214/ajr.159.1.1609713, PubMed 1609713

Tanum G, Stenwig AE, Børmer OP, Tveit KM (1992)
Carcinoembryonic antigen in anal carcinoma
Acta Oncol, 31 (3), 333-5
DOI 10.3109/02841869209108181, PubMed 1622654

Tanum G, Tveit KM, Giercksky KE (1992)
[Endocavitary radiotherapy of rectal cancer]
Tidsskr Nor Laegeforen, 112 (12), 1599-600
PubMed 1615515

Publications 1991

Jacobsen AB, Tveit KM, Pettersen EO, Fossa SD, Ous S (1991)
Colony formation in urinary bladder carcinoma. Relationship to DNA flow cytometry, stage and histopathology
Anticancer Res, 11 (2), 777-81
PubMed 2064333

Nesland JM, Ottestad L, Børresen AL, Tvedt KE, Holm R, Heikkilä R, Tveit K (1991)
The c-erbB-2 protein in primary and metastatic breast carcinomas
Ultrastruct Pathol, 15 (3), 281-9
DOI 10.3109/01913129109021890, PubMed 1678562

Nesland JM, Ottestad L, Heikilla R, Holm R, Tveit K, Børresen AL (1991)
C-erbB-2 protein and neuroendocrine expression in breast carcinomas
Anticancer Res, 11 (1), 161-7
PubMed 1673329

Tanum G, Tveit K, Karlsen KO (1991)
Diagnosis of anal carcinoma--doctor's finger still the best?
Oncology, 48 (5), 383-6
DOI 10.1159/000226964, PubMed 1745485

Tanum G, Tveit K, Karlsen KO, Hauer-Jensen M (1991)
Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity
Cancer, 67 (10), 2462-6
DOI 10.1002/1097-0142(19910515)67:10<2462::aid-cncr2820671012>3.0.co;2-1, PubMed 2015547

Tanum G, Tveit KM (1991)
[Anus cancer]
Tidsskr Nor Laegeforen, 111 (10), 1211
PubMed 2042124

Publications 1990

Børresen AL, Ottestad L, Gaustad A, Andersen TI, Heikkilä R, Jahnsen T, Tveit KM, Nesland JM (1990)
Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis
Br J Cancer, 62 (4), 585-90
DOI 10.1038/bjc.1990.334, PubMed 1977466

Sager EM, Fosså SD, Kaalhus O, Tveit KM (1990)
Computed tomography of the urinary bladder shortly after radiation therapy for rectal carcinoma
Acta Radiol, 31 (6), 585-8
PubMed 2278782

Tanum G, Tveit KM, Høst H, Pettersen EO (1990)
Benzylidene-glucose: no effect after all?
Am J Clin Oncol, 13 (2), 161-3
DOI 10.1097/00000421-199004000-00014, PubMed 2316482

Tveit KM, Ottestad L (1990)
Drug sensitivity testing of human breast cancer
Acta Oncol, 29 (3), 335-8
DOI 10.3109/02841869009090010, PubMed 2194534

Publications 1989

Ottestad L, Tveit KM, Hannisdal E, Skrede M, Nesland JM, Gundersen S, Pihl A (1989)
Colony forming ability of human breast carcinomas: lack of prognostic significance
Br J Cancer, 60 (2), 216-9
DOI 10.1038/bjc.1989.254, PubMed 2765368

Tveit KM, Kaern J, Hoifodt HK, Pettersen EO, Abeler V, Davy M, Hannisdal E, Trope C (1989)
Colony-forming ability of human ovarian carcinomas in the Courtenay soft agar assay
Anticancer Res, 9 (6), 1577-82
PubMed 2483300

Tveit KM, Karlsen KO, Fosså SD, Flokkmann A, Guldvog I, Haffner J (1989)
Primary treatment of carcinoma of the anus by combined radiotherapy and chemotherapy
Scand J Gastroenterol, 24 (10), 1243-7
DOI 10.3109/00365528909090794, PubMed 2513640

Publications 1988

Fosså SD, Tveit K, Börmer O, Moxnes A, Jørgensen NP, Orjaseter H, Kristoffersen DT (1988)
Relative bioavailability of oral low dose methotrexate. A comparison of 2 different formulations
Eur J Clin Pharmacol, 34 (5), 517-9
DOI 10.1007/BF01046713, PubMed 3203714

Ottestad L, Tveit KM, Høifødt HK, Nesland JM, Vaage S, Høie J, Lund E, Pihl A (1988)
Cultivation of human breast carcinoma in soft agar. Experience with 237 fresh tumour specimens
Br J Cancer, 58 (1), 8-12
DOI 10.1038/bjc.1988.151, PubMed 3048354

Ottestad LO, Tveit KM, Nesland JM, Dybsjord I, Børmer O, Høie J, Pihl A (1988)
An immunocytochemical method for assaying oestrogen receptors in breast cancers. A comparison with the steroid binding assay
Histol Histopathol, 3 (3), 269-74
PubMed 2980233

Tveit KM, Gundersen S, Høie J, Pihl A (1988)
Predictive chemosensitivity testing in malignant melanoma: reliable methodology--ineffective drugs
Br J Cancer, 58 (6), 734-7
DOI 10.1038/bjc.1988.299, PubMed 3224078

Publications 1987

Wanderås EH, Fosså SD, Tveit KM, Flokkmann A (1987)
Sequential 5-fluorouracil and methotrexate. Negative experience in metastatic colorectal cancer
Acta Oncol, 26 (4), 289-93
DOI 10.3109/02841868709089977, PubMed 3500730

Publications 1985

Endresen L, Tveit KM, Rugstad HE, Pihl A (1985)
Chemosensitivity measurements of human tumour cells by soft agar assays are influenced by the culture conditions
Br J Cancer, 51 (6), 843-52
DOI 10.1038/bjc.1985.130, PubMed 4005141

Rofstad EK, Wahl A, Tveit KM, Monge OR, Brustad T (1985)
Survival curves after X-ray and heat treatments for melanoma cells derived directly from surgical specimens of tumours in man
Radiother Oncol, 4 (1), 33-44
DOI 10.1016/s0167-8140(85)80060-8, PubMed 4035001

Tveit KM, Pettersen EO, Fosså SD, Pihl A (1985)
Selection of tumour cell subpopulations occurs during cultivation of human tumours in soft agar. A DNA flow cytometric study
Br J Cancer, 52 (5), 701-5
DOI 10.1038/bjc.1985.246, PubMed 4063145

Publications 1984

Jellum E, Thorsrud AK, Vatn MH, Grimstad IA, Brennhovd I, Tveit KM, Pihl A (1984)
Detection of cancer-related proteins by two-dimensional electrophoresis
Ann N Y Acad Sci, 428, 173-85
DOI 10.1111/j.1749-6632.1984.tb12294.x, PubMed 6588905

Wibe E, Berg JP, Tveit KM, Nesland JM, Lunde S (1984)
Multicellular spheroids grown directly from human tumour material
Int J Cancer, 34 (1), 21-6
DOI 10.1002/ijc.2910340105, PubMed 6746116

Publications 1983

Endresen L, Bakka A, Glennås A, Tveit KM, Rugstad HE (1983)
Stability of cadmium resistance and metallothionein levels in vitro and in vivo
Toxicol Appl Pharmacol, 67 (2), 274-83
DOI 10.1016/0041-008x(83)90234-x, PubMed 6836582

Fodstad O, Rofstad EK, Tveit KM, Pihl A (1983)
Spontaneous alteration in growth rates of two human melanoma xenografts. Concurrent changes in chemosensitivity
Eur J Cancer Clin Oncol, 19 (8), 1175-8
DOI 10.1016/0277-5379(83)90046-9, PubMed 6684563

Tveit KM (1983)
[Individualized drug therapy of cancer based on an in vitro test]
Tidsskr Nor Laegeforen, 103 (2), 113-6
PubMed 6845299

Tveit KM, Gundersen S, Vaage S (1983)
[Drug therapy of malignant melanoma based on a cell culture test]
Tidsskr Nor Laegeforen, 103 (2), 117-9
PubMed 6845300

Publications 1982

Tveit KM (1982)
Studies of human melanoma cells cultivated in monolayer and in soft agar: the usefulness of in vitro tests for predicting clinical responses to cancerostatic agents
[s.n.], Oslo, Fl. pag.
BIBSYS 83500676x

Tveit KM, Fodstad O, Lotsberg J, Vaage S, Pihl A (1982)
Colony growth and chemosensitivity in vitro of human melanoma biopsies. Relationship to clinical parameters
Int J Cancer, 29 (5), 533-8
DOI 10.1002/ijc.2910290508, PubMed 7095899

Publications 1981

Tveit KM, Endresen L, Rugstad HE, Fodstad O, Pihl A (1981)
Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: malignant melanomas
Br J Cancer, 44 (4), 539-44
DOI 10.1038/bjc.1981.223, PubMed 7295510

Tveit KM, Fodstad O, Pihl A (1981)
The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas
Int J Cancer, 28 (4), 403-8
DOI 10.1002/ijc.2910280402, PubMed 7309286

Tveit KM, Fodstad O, Pihl A (1981)
Cultivation of human melanomas in soft agar. Factors influencing plating efficiency and chemosensitivity
Int J Cancer, 28 (3), 329-34
DOI 10.1002/ijc.2910280312, PubMed 7319675

Tveit KM, Pihl A (1981)
Do cell lines in vitro reflect the properties of the tumours of origin? A study of lines derived from human melanoma xenografts
Br J Cancer, 44 (6), 775-86
DOI 10.1038/bjc.1981.276, PubMed 7326190

Publications 1980

Tveit KM, Fodstad O, Brøgger A, Olsnes S (1980)
Human embryonal carcinoma grown in athymic mice and in vitro
Cancer Res, 40 (3), 949-53
PubMed 7471109

Tveit KM, Fodstad O, Johannessen JV, Olsnes S (1980)
A human melanoma cell line established from xenograft in athymic mice
Br J Cancer, 41 (5), 724-33
DOI 10.1038/bjc.1980.134, PubMed 7426299

Tveit KM, Fodstad O, Olsnes S, Pihl A (1980)
In vitro sensitivity of human melanoma xenografts to cytotoxic drugs. Correlation with in vivo chemosensitivity
Int J Cancer, 26 (6), 717-22
DOI 10.1002/ijc.2910260604, PubMed 7216540

Publications 1978

Olsnes S, Tveit KM (1978)
[Teratocarcinoma as a model system in studies of malignancy and differentiation]
Tidsskr Nor Laegeforen, 98 (22), 998-1001
PubMed 684708

Page visits: 11917